Table 3.
Logistic regression of common adverse reactions
| Adverse events | Gene type | B | SE | Z | P | OR (95%CI) |
| *After adjusting the number of treatment lines, treatment plan, smoking, gender, tumor type and hyperbilirubinemia. | ||||||
| *Vomit | UGT1A1*6 | 0.524 | 0.438 | 1.198 | 0.231 | 1.69 (0.72-3.99) |
| UGT1A1*28 | 1.491 | 0.568 | 2.623 | 0.009 | 4.44 (1.46-13.52) | |
| *Vomit grade | UGT1A1*6 | 1.921 | 0.573 | 3.353 | 0.001 | 6.83 (2.22-20.98) |
| UGT1A1*28 | 1.081 | 0.577 | 1.874 | 0.061 | 2.95 (0.95-9.14) | |
| *Diarrhea | UGT1A1*6 | 0.128 | 0.453 | 0.283 | 0.777 | 1.14 (0.47-2.76) |
| UGT1A1*28 | -0.474 | 0.499 | -0.949 | 0.343 | 0.62 (0.23-1.66) | |
| *Mucositis | UGT1A1*6 | 0.601 | 0.447 | 1.346 | 0.178 | 1.82 (0.76-4.38) |
| UGT1A1*28 | 1.371 | 0.484 | 2.831 | 0.005 | 3.94 (1.52-10.17) | |
| *Neutropenia grade | UGT1A1*6 | 1.057 | 0.459 | 2.303 | 0.021 | 2.88 (1.17-7.08) |
| UGT1A1*28 | 0.575 | 0.506 | 1.136 | 0.256 | 1.78 (0.66-4.79) | |